| name | bio-clinical-databases-pharmacogenomics |
| description | Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk. |
| tool_type | mixed |
| primary_tool | PharmCAT |
Version Compatibility
Reference examples tested with: PharmCAT 2.13+, Cyrius 1.1+ (Chen 2021), Aldy 4.0+, Stargazer 2.0+, StarPhase 1.0+ (PacBio HiFi), HIBAG 1.40+, requests 2.31+, pandas 2.2+. CPIC guideline versions are gene-specific; PharmVar releases are quarterly. DPYD dosing uses the CPIC gene activity-score system (Amstutz 2018 Clin Pharmacol Ther 103:210, the 2017-update guideline); the 2025 TPMT/NUDT15 update (Maillard 2026) refines compound-IM dosing.
Before using code patterns, verify installed versions match. If versions differ:
- Python:
pip show <package> then help(module.function) to check signatures
- CLI:
<tool> --version then <tool> --help to confirm flags
If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying. PharmVar is the authoritative star-allele source (https://www.pharmvar.org); the older Human CYP Allele Nomenclature Database was deprecated in 2017.
Pharmacogenomics; Star Alleles, Activity Scores, and CPIC/DPWG Guidance
'What is my patient's CYP2D6 metabolizer status and should I adjust their tamoxifen dose?' -> Call star alleles (haplotype-level), translate diplotype -> activity score -> phenotype, apply CPIC + DPWG dosing.
- CLI (recommended):
pharmcat -vcf input.vcf.gz -o pharmcat_out; CPIC-recommended, single-tool reporting
- CLI (CYP2D6 SV-aware):
cyrius -m sample.bam -o cyrius_out; mandatory addition for CYP2D6
- CLI (multi-gene CN-aware):
aldy genotype -p illumina sample.bam; alternative
- CLI (long-read 8-field): PacBio HiFi
starphase; transplant-grade including HLA
- R (SNP-array): HIBAG for HLA-B57:01/B15:02/B58:01/A31:01 imputation
- API:
requests.get('https://api.pharmgkb.org/v1/data/clinicalAnnotation', ...)
Governance: CPIC vs DPWG vs PharmGKB vs FDA
These four authorities are routinely conflated. They differ in scope, scale, and recommendations:
| Authority | Scope | Output | Anchors |
|---|
| CPIC (US Clinical Pharmacogenetics Implementation Consortium) | Once a result is available, what to prescribe | Level A/B/C/D gene-drug pair + strength of recommendation per phenotype + evidence quality | ~26 guidelines, ~25 genes, 100+ drugs as of 2026 |
| DPWG (Dutch Pharmacogenetics Working Group) | Whether to test AND what to prescribe | 5-pt (0-4) evidence + 7-pt (AA-F) clinical-relevance scale | G-Standaard (Dutch EHR-integrated); RCT-validated via PREPARE |
| PharmGKB clinical annotation levels | Evidence cataloguing | 1A/1B/2A/2B/3/4 | 1A = guideline OR medical-society OR PGRN/eMERGE implementation; NOT pure evidence |
| FDA Table of Pharmacogenomic Biomarkers | Drug label info | ~300 drugs (informational) | NOT an actionability list; many entries are dosing-suggestion-only |
| FDA Table of Pharmacogenetic Associations | Actionable subset | Closer to CPIC | Compare head-to-head with CPIC |
Bank et al 2018 Clin Pharmacol Ther 103:599 (DOI 10.1002/cpt.762) is the canonical CPIC-vs-DPWG comparison. Notable disagreements:
- CYP2D6 IM + multiple antidepressants: DPWG actionable; CPIC says insufficient evidence.
- HLA-B*15:11 carbamazepine: DPWG actionable; CPIC silent.
- CYP2C19 IM + voriconazole: dosing magnitudes differ 25-50%.
Common PGx-evidence critiques: (1) EUR over-representation in discovery cohorts; (2) most PGx RCTs are open-label / prescriber-unblinded; (3) publication bias in antiseizure PGx may overstate effects ~2x; (4) subjective composite endpoints.
PharmGKB Clinical Annotation Levels: What 1A Actually Means
| Level | Requirement |
|---|
| 1A | Variant-drug pair appears in CPIC guideline OR medical-society guideline OR is implemented at a PGRN/eMERGE site |
| 1B | Replication in multiple cohorts; preponderance of evidence; no formal guideline yet |
| 2A | Replicated association in a VIP (Very Important Pharmacogene) |
| 2B | Replicated association in non-VIP gene |
| 3 | Single significant association OR mixed-evidence variant-drug pair |
| 4 | In vitro / case report / molecular evidence only |
1A does NOT require RCT evidence; mechanism + guideline status suffices.
Star Allele Nomenclature (PharmVar)
PharmVar (https://www.pharmvar.org) is authoritative for: CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2W1, CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYP4A11, CYP4F2, CYP19A1, CYP26A1, DPYD, NUDT15, SLCO1B1, TPMT.
A star allele is a haplotype, not a single variant. Suballeles (*1.001, *1.002, etc.) encode the exact SNV+indel pattern within a defined functional haplotype.
*The 1 reference is the PharmVar consensus reference, NOT biological wild type. Defined as the absence of all known functional variants at the locus.
CYP2D6 Activity Scores (Caudle 2020 Clin Transl Sci; DOI 10.1111/cts.12692)
| Phenotype | Activity score (AS) range |
|---|
| PM (Poor Metabolizer) | 0 |
| IM (Intermediate Metabolizer) | 0 < AS < 1.25 |
| NM (Normal Metabolizer) | 1.25 <= AS <= 2.25 |
| UM (Ultra-rapid) | AS > 2.25 |
Key per-allele activity values (selected):
| Allele | Activity | Notes |
|---|
| *1, *2, *35 | 1.0 | Normal |
| *3, *4, *5 (gene deletion), *6, *7, *8, *11, *12, *15, *19, *20, *36, *40, *42 | 0 | No function |
| *9, *41, *17, *29 | 0.5 | Decreased function (substrate-specific caveats for *17) |
| *10 | 0.25 | Caudle 2020 RESET from 0.5 to 0.25; reclassified large fractions of East-Asian populations to IM |
| *68 | 0 | Hybrid; non-functional |
*4xN is clinically silent: a no-function allele multiplied by N is still no-function. Reporting *4xN as UM is the most-common reportable error in clinical PGx.
CYP2D6 Structural Complexity
CYP2D6 on 22q13.2 sits adjacent to the highly-similar CYP2D7 pseudogene. Four classes of structural variant that no SNV-only caller can resolve:
- Gene deletion (*5): ~13 kb deletion; activity 0; diagnostic REP6/REP7 breakpoint.
- Gene duplication/multiplication (*1xN, *2xN, *4xN, *10xN, *17xN, *35xN, *36xN): Tandem copies; clinical impact depends on which allele is amplified; *4xN is clinically silent.
- CYP2D7 -> CYP2D6 hybrids (*13): Pseudogene fused 5'; non-functional.
- CYP2D6 -> CYP2D7 hybrids (*36, *61, *63, *68, *83): 5' CYP2D6 with 3' pseudogene exon 9 conversion; typically embedded in duplications upstream of *10 (East Asian) or upstream of *4 (European).
GATK / DeepVariant alone cannot call any of these. They operate on multi-mapper-filtered BAMs; 97%+ identity between CYP2D6 and CYP2D7 produces silent miscalls of every *5, *13, *36, *68, *4xN sample.
Algorithmic Taxonomy: Star Allele Callers
| Tool | CYP2D6 SV | CYP2D6 CN | Other PGx genes | Phased | Validation | Fails when |
|---|
| PharmCAT (Sangkuhl 2020 Clin Pharmacol Ther) | No (consumes outside SV calls) | No | 21 CPIC genes; full clinical reporting | Phased or unphased VCF | High; CPIC reference | CYP2D6 SV-rich samples need Cyrius/StellarPGx upstream |
| Cyrius (Chen 2021 Pharmacogenomics J) | Yes (99.3% concordance) | Yes | CYP2D6 only | Phased haplotypes | GeT-RM 99.3% | Other genes (single-purpose tool) |
| BCyrius (PubMed 39901590, 2025) | Yes (extended) | Yes | CYP2D6 only | Phased | Extended SV diversity | Other genes |
| Aldy v4 (Numanagic 2018 Nat Commun) | Yes | Yes | CYP2D6, CYP2A6, CYP2B6, etc. | Phased | GeT-RM 82-87% (CYP2D6) | Less accurate than Cyrius for CYP2D6 |
| Stargazer (Lee 2019 Genet Med) | Limited | Yes | ~50 PGx genes | Statistical phasing | ~84% (CYP2D6) | Fails on rare alleles; statistical phasing is unstable |
| StellarPGx | Yes (~99%) | Yes | CYP2D6 + others | Phased | GeT-RM ~99% | Less widely deployed than Cyrius |
| Astrolabe (proprietary, formerly Constellation) | Yes | Yes | Multi-gene | Proprietary | Industry-validated | License required |
| StarPhase (PacBio HiFi 2024+) | Yes | Yes | All CPIC Level A genes + HLA | Native phasing | Long-read gold standard | Requires PacBio HiFi |
Canonical clinical workflow 2024-2026: PharmCAT for the panel + Cyrius (or StellarPGx) for CYP2D6 SVs + dedicated HLA typer (T1K, OptiType, HLA-LA) for HLA.
Twesigomwe 2020 npj Genom Med: inter-tool discordance 10-18% on CYP2D6; nearly all in samples carrying SVs.
HLA-Drug Associations: Mechanistically Distinct from CYP
HLA associations are idiosyncratic immune reactions, not dose-response phenomena. Effect sizes (OR 50-1000+) far exceed any CYP polymorphism. Testing rationale is screen-and-avoid, not dose-adjust.
| Allele | Drug | Reaction | Population | Landmark |
|---|
| HLA-B*57:01 | Abacavir | HSS | All ancestries (5-8% NFE) | Mallal 2008 NEJM (PREDICT-1) |
| HLA-B*15:02 | Carbamazepine, oxcarbazepine, phenytoin, lamotrigine (weaker) | SJS/TEN | Han Chinese, Thai, Malay, Indian (>=5%) | Chung 2004 Nature; FDA black-box 2007 |
| HLA-A*31:01 | Carbamazepine | DRESS, MPE, SJS/TEN | Europeans (2-5%), Japanese | McCormack 2011 NEJM |
| HLA-B*58:01 | Allopurinol | SJS/TEN, DRESS | Han Chinese (10-15%), Thai, Korean | Hung 2005 PNAS (OR ~580) |
| HLA-B*13:01 | Dapsone | DDS | Han Chinese, SE Asian | Zhang 2013 NEJM |
| HLA-B*35:02 (NOT *35:01) | Minocycline | DILI | All | Urban 2017 J Hepatol |
| HLA-B*35:01 | TMP-SMX | DILI, DRESS-like | African American | Li 2021 Hepatology |
| HLA-B*14:01 | TMP-SMX | DILI | European American (OR 9.20) | Li 2021 |
| HLA-A*33:01/03 | Terbinafine | DILI | Multi-ancestry | Nicoletti 2017 |
| HLA-DRB1*15:01-DQB1*06:02 haplotype | Amoxicillin-clavulanate | DILI | Europeans | Stephens 2013 |
| HLA-B*15:13 | Phenytoin | SJS | Malaysian | Chang 2017 |
Critical: HLA screening requires 4-field resolution. *57:01 (abacavir risk) vs *57:03 (no risk); *35:02 (minocycline DILI) vs *35:01 (TMP-SMX DILI). See clinical-databases/hla-typing for typing.
Non-CYP Pharmacogenes: Variant-Level Detail
DPYD (5-FU / Capecitabine / Tegafur); Activity Score Framework
The CPIC DPYD guideline (Amstutz 2018 Clin Pharmacol Ther 103:210) uses a gene activity score system. Activity values: normal-function = 1.0, decreased = 0.5, no function = 0.
| Variant | rsID | Allele | Activity |
|---|
| c.1905+1G>A | rs3918290 | DPYD*2A | 0 (splice disruption) |
| c.1679T>G | rs55886062 | DPYD*13 (p.I560S) | 0 |
| c.2846A>T | rs67376798 | (p.D949V) | 0.5 |
| c.1129-5923C>G / c.1236G>A (HapB3) | rs56038477 / rs75017182 | HapB3 | 0.5 |
Gene AS = sum of two lowest activities. Recommended dose: AS 2 = full dose; AS 1.5 = 50% start + TDM; AS 1.0 = 50% start + TDM; AS 0 = avoid.
c.85T>C (DPYD*9A) is NOT in the CPIC actionable set despite frequent commercial reporting; evidence does not support clinical decrement.
EU universal pre-treatment testing standard since Henricks 2018 Lancet Oncol (genotype-guided dosing lowered severe fluoropyrimidine toxicity in DPYD variant carriers, e.g. DPYD*2A grade >=3 toxicity RR 2.87 -> 1.31) and EMA 2020 endorsement. US lags; ASCO/NCCN moved 2022-2024.
TPMT + NUDT15 (Thiopurines); 2025 Update
Maillard 2026 Clin Pharmacol Ther update emphasizes greater dose reduction for compound TPMT/NUDT15 IM.
| Gene | Variant | Activity | Population |
|---|
| TPMT *2 | c.238G>C | 0 | -- |
| TPMT *3A | c.460G>A + c.719A>G | 0 | EUR-common |
| TPMT *3B | c.460G>A | 0 | -- |
| TPMT *3C | c.719A>G | 0 | AFR / EAS dominant |
| NUDT15 *3 | c.415C>T (rs116855232) | 0 | ~9.8% East Asian; <1% EUR |
NUDT15 *3 is the dominant thiopurine determinant in East Asians; TPMT-alone testing misses these patients (Yang 2015 J Clin Oncol).
UGT1A1 (Irinotecan, Atazanavir)
- *28 (TA7 promoter repeat vs *1 = TA6, *37 = TA8); EUR-common
- *6 (c.211G>A, p.G71R); East Asian dominant
- Severe neutropenia in *28/*28 at irinotecan >=180 mg/m^2
CYP2C19 + Clopidogrel; The Most-Litigated Pair
- Pare 2010 NEJM: no benefit of clopidogrel in *2 carriers in CURE/ACTIVE-A.
- TAILOR-PCI (Pereira 2020 JAMA): 5,302 patients post-PCI; primary endpoint MACE @12mo HR 0.66, p=0.06 (negative by pre-specified alpha) but positive in sensitivity analyses.
- Pereira NL et al 2021 meta-analysis (7 RCTs, 15,949 patients): ~30% MACE reduction in CYP2C19 LOF carriers (JACC Cardiovasc Interv 14:739).
- Consensus 2024 (ACC/AHA/ESC): genotype-guided therapy reasonable; strongest in post-PCI ACS.
Warfarin (CYP2C9 + VKORC1 + CYP4F2)
- EU-PACT 2013 NEJM: PGx dosing positive (European).
- COAG 2013 NEJM: PGx dosing negative; worse in African Americans because algorithm omitted CYP2C9 *5, *6, *8, *11 alleles common in African ancestry. Paradigmatic ancestry-algorithm failure (Daneshjou 2014 Blood).
- IWPC algorithm explains 47-55% of dose variance.
SLCO1B1 + Simvastatin
- rs4149056 (c.521T>C, p.V174A); OR 4.5 per C allele for myopathy on 80 mg simvastatin (SEARCH 2008 NEJM).
- 2022 CPIC update broadened to all statins with SLCO1B1 substrate behavior.
Other Actionable
- *CYP2B6 6 (c.516G>T + c.785A>G): efavirenz dose 600 -> 400 mg in *6/*6 (ENCORE1).
- *CYP3A5 3 (rs776746): non-expressers (*3, *6, *7) are the common state in non-AFR; expressers need 1.5-2x higher tacrolimus dose.
- G6PD (CPIC 2022 Gammal 2023): X-linked; female heterozygotes have mosaic activity that single-timepoint assay misclassifies.
Decision Tree by Scenario
| Scenario | Recommended path | Why |
|---|
| Multi-gene PGx panel from VCF | PharmCAT | CPIC-recommended; 21 genes + full clinical reporting |
| CYP2D6 with structural variants | Cyrius (or StellarPGx) | Only tools with reliable SV calling from short-read |
| All CPIC Level A + HLA from one sample | PacBio HiFi + StarPhase | Long-read single-pass typing |
| Pre-emptive panel for cohort | PREPARE-style 12-gene panel | Swen 2023 RCT-validated |
| HLA-B*57:01 abacavir screen | T1K or OptiType (4-field); HIBAG if SNP-array | Need 4-field specificity |
| African-ancestry warfarin | IWPC algorithm + CYP2C9 *5/*6/*8/*11 explicit | COAG failure paradigm |
| East Asian thiopurine | NUDT15 + TPMT | NUDT15 *3 is dominant in EAS |
| Compound IM (TPMT + NUDT15) | Apply 2025 update | More aggressive dose reduction than single-gene IM |
| Activity score interpretation | Caudle 2020 thresholds for CYP2D6; gene-specific for others | Per CPIC |
PharmCAT Workflow (Recommended Multi-Gene Pipeline)
Goal: Generate CPIC-compliant pharmacogenomic report from a phased or unphased VCF covering 21 PGx genes.
Approach: Run PharmCAT on the VCF; supplement CYP2D6 with Cyrius output if SVs suspected; cross-reference HLA from separate typing.
pharmcat_vcf_preprocessor.py \
-vcf input.vcf.gz \
-refFna GRCh38.fa \
-o pharmcat_input/
java -jar pharmcat.jar \
-vcf pharmcat_input/input.preprocessed.vcf.bgz \
-o pharmcat_output/
For CYP2D6 SV-rich samples, run Cyrius separately and pass outside calls to PharmCAT:
cyrius -m sample.bam -o cyrius_out --threads 8
java -jar pharmcat.jar \
-vcf pharmcat_input/input.preprocessed.vcf.bgz \
-po cyrius_out/cyrius_for_pharmcat.tsv \
-o pharmcat_output_with_cyrius/
CYP2D6 Activity Score Calculation
Goal: Convert CYP2D6 diplotype to activity score and phenotype with Caudle 2020 conventions.
Approach: Look up per-allele activity values; handle copy-number duplications; apply Caudle 2020 phenotype bins.
CYP2D6_ACTIVITY = {
'*1': 1.0, '*2': 1.0, '*35': 1.0,
'*3': 0.0, '*4': 0.0, '*5': 0.0, '*6': 0.0, '*7': 0.0, '*8': 0.0,
'*11': 0.0, '*12': 0.0, '*15': 0.0, '*19': 0.0, '*20': 0.0,
'*36': 0.0, '*40': 0.0, '*42': 0.0, '*68': 0.0,
'*9': 0.5, '*41': 0.5, '*17': 0.5, '*29': 0.5,
'*10': 0.25,
'*13': 0.0,
}
def cyp2d6_activity(diplotype):
'''Convert CYP2D6 diplotype to activity score.
Accepts e.g. '*1/*4' or '*2xN/*10' or '*4xN/*10'. Copy-number-aware:
- *4xN is clinically silent (no-function * N = 0)
- *1xN, *2xN multiply functional activity
'''
left, right = diplotype.split('/')
return _allele_activity(left) + _allele_activity(right)
def _allele_activity(allele_str):
'''Handle copy-number suffix xN. *4xN remains 0 (the most common mis-classification).'''
if 'x' in allele_str:
base, n = allele_str.split('x')
copies = int(n) if n != 'N' else 2
return CYP2D6_ACTIVITY.get(base, 1.0) * copies
return CYP2D6_ACTIVITY.get(allele_str, 1.0)
def cyp2d6_phenotype(activity_score):
'''Caudle 2020 phenotype bins.'''
if activity_score == 0:
return 'Poor Metabolizer'
if activity_score < 1.25:
return 'Intermediate Metabolizer'
if activity_score <= 2.25:
return 'Normal Metabolizer'
return 'Ultrarapid Metabolizer'
diplotype = '*4xN/*10'
score = cyp2d6_activity(diplotype)
print(f'{diplotype}: AS={score}, phenotype={cyp2d6_phenotype(score)}')
DPYD Activity Score (CPIC)
DPYD_2024_ACTIVITY = {
'c.1905+1G>A': 0.0,
'c.1679T>G': 0.0,
'c.2846A>T': 0.5,
'HapB3': 0.5,
}
def dpyd_activity(variants):
'''Compute DPYD gene activity score from observed variants.
Sum the two lowest activities across the two alleles. CPIC dosing:
- AS 2.0: full dose
- AS 1.5: 50% start + TDM
- AS 1.0: 50% start + TDM
- AS 0.0: avoid
'''
activities = sorted([DPYD_2024_ACTIVITY.get(v, 1.0) for v in variants])
return sum(activities[:2])
def dpyd_dosing(activity_score):
if activity_score >= 1.99:
return 'Full dose'
if activity_score >= 1.0:
return '50% starting dose + therapeutic drug monitoring'
return 'Avoid fluoropyrimidines'
PharmGKB API for Drug-Gene Pair Lookup
import requests
PHARMGKB = 'https://api.pharmgkb.org/v1'
def clinical_annotation(gene_symbol):
'''Query PharmGKB clinical annotations by gene.'''
r = requests.get(f'{PHARMGKB}/data/clinicalAnnotation',
params={'view': 'base', 'location.genes.symbol': gene_symbol},
timeout=30)
return r.json().get('data', [])
def cpic_guideline(gene_symbol):
'''Query CPIC guidelines via PharmGKB.'''
r = requests.get(f'{PHARMGKB}/data/guideline',
params={'view': 'base', 'relatedGenes.symbol': gene_symbol, 'source': 'CPIC'},
timeout=30)
return r.json().get('data', [])
Per-Operation Failure Modes
*1. 4xN -> "Ultrarapid Metabolizer"
- Trigger: Pipeline reports CYP2D6 *4xN as UM.
- Mechanism: *4 has activity 0; *4 x N = still 0. Only functional alleles (*1, *2, *35) become UM when amplified.
- Symptom: Patient labeled as needing dose reduction when they should be PM/IM.
- Fix: Look up per-allele activity BEFORE multiplying by N; *4xN = 0; AS depends entirely on the other allele.
2. Calling CYP2D6 from short-read without SV-aware tool
- Trigger: Use GATK + PharmCAT only on CYP2D6.
- Mechanism: 97%+ CYP2D6/CYP2D7 identity; SVs (deletion, duplications, hybrids) silently miscalled.
- Symptom: ~10-18% of samples miscalled (Twesigomwe 2020); concentrated in samples with SVs.
- Fix: Add Cyrius (or StellarPGx) for CYP2D6; pass outside calls to PharmCAT.
3. Pre-2020 *10 activity value
- Trigger: Use activity = 0.5 for CYP2D6 *10.
- Mechanism: Caudle 2020 reset *10 from 0.5 to 0.25 based on metabolic-ratio evidence.
- Symptom: East-Asian samples mis-classified as NM (when should be IM).
- Fix: Use Caudle 2020 activity table; *10 = 0.25.
4. EUR-only DPYD panel
- Trigger: Pre-treat fluoropyrimidine using CPIC-core 4-variant panel only.
- Mechanism: 4-variant panel captures EUR DPD-deficient carriers but misses additional DPYD variants enriched in non-European populations (Offer 2014 identified ~30 such deleterious variants).
- Symptom: African-ancestry patients suffer severe toxicity despite "negative" PGx.
- Fix: Use extended panel for AFR cohorts; supplement with phenotype testing (uracil/dihydrouracil plasma ratio).
5. TPMT testing without NUDT15
- Trigger: Pre-treat thiopurines using TPMT-only PGx in East Asian patient.
- Mechanism: NUDT15 *3 (9.8% EAS, <1% EUR) is the dominant determinant in EAS.
- Symptom: EAS patients TPMT-wildtype suffer severe myelosuppression.
- Fix: Always test NUDT15 alongside TPMT; apply Maillard 2026 compound-IM rules.
6. HLA-B*57 -> "abacavir risk" (4-field underspecified)
- Trigger: Screen reports "B*57 present" as contraindication.
- Mechanism: B57:01 (HSS risk), B57:02, B*57:03 (no HSS risk).
- Symptom: False contraindication; patient denied effective therapy.
- Fix: Report 4-field; B*57:01 specifically.
*7. CYP3A5 3 / non-expresser confusion
- Trigger: Apply "CYP3A5 normal metabolizer" to *3/*3 in tacrolimus dosing.
- Mechanism: *3/*3 are NON-EXPRESSERS (most common state in non-AFR); expressers (any *1) need 1.5-2x higher dose.
- Symptom: Tacrolimus over-dosing in expressers; under-dosing in non-expressers.
- Fix: Apply CPIC 2015 (Birdwell) tacrolimus dosing; flag expresser status.
8. Activity-based vs allele-based confusion
- Trigger: Sum activities across substrate-non-specific assumption for *17.
- Mechanism: CYP2D6 *17 shows substrate-dependent activity (reduced for some substrates, near-normal for others).
- Symptom: Substrate-specific dose recommendations applied generically.
- Fix: Use substrate-specific guidance where available; flag *17 in AFR cohorts.
Reconciliation: When Tools Disagree
| Pattern | Likely cause | Action |
|---|
| Cyrius vs Aldy CYP2D6 disagree | SV-rich sample; Aldy less accurate | Trust Cyrius |
| PharmCAT vs CPIC website disagree on phenotype | PharmCAT version lag or *10 activity value drift | Update PharmCAT to current release |
| CPIC vs DPWG dosing differ | Independent guideline bodies | Cite both; use jurisdiction-appropriate one |
| Patient phenotype doesn't match genotype | Drug-drug interaction; clearance physiology; non-pharmacogenetic factor | Consider phenoconversion; clinical reassessment |
| TPMT-only test vs IM phenotype | Missed NUDT15 in EAS | Re-test with NUDT15 |
| *4xN reported as UM | Tool bug | Use SV-aware tool and Caudle 2020 activity table |
| HLA-B*57 reported without 4-field | Insufficient resolution | Re-type at 4-field minimum |
Quantitative Thresholds and Conventions
| Threshold | Convention | Source |
|---|
| Cyrius CYP2D6 accuracy | 99.3% on GeT-RM reference samples | Chen 2021 Pharmacogenomics J |
| Aldy CYP2D6 accuracy | 82-87% on GeT-RM | Twesigomwe 2020 |
| Stargazer CYP2D6 accuracy | ~84% on GeT-RM | Twesigomwe 2020 |
| Inter-tool CYP2D6 discordance | 10-18% (concentrated in SV samples) | Twesigomwe 2020 |
| PREPARE ADR reduction | OR 0.70 (95% CI 0.54-0.91) for actionable interactions | Swen 2023 Lancet |
| PREPARE actionable variant rate | 93.5% of patients had >=1 actionable variant | Swen 2023 |
| TAILOR-PCI primary endpoint | HR 0.66 (95% CI 0.43-1.02), p=0.06 (negative) | Pereira 2020 JAMA |
| Pereira 2021 meta-analysis | ~30% MACE reduction in CYP2C19 LOF carriers | Pereira 2021 JACC Cardiovasc Interv 14:739 |
| Henricks 2018 DPYD outcome | Per-variant toxicity reduction (DPYD*2A grade >=3 RR 2.87 -> 1.31) | Henricks 2018 Lancet Oncol |
| NUDT15 *3 frequency | ~9.8% East Asian vs <1% EUR | Relling 2019 CPIC Clin Pharmacol Ther 105:1095 |
| HLA-B*57:01 OR for abacavir HSS | ~100 (case-control) | Mallal 2002 Lancet 359:727 |
Common Errors
| Symptom | Cause | Solution |
|---|
| CYP2D6 reported as UM in samples with *4xN | Tool not SV-aware OR Caudle 2020 not applied | Use Cyrius; check *4xN handling |
| East-Asian patient labeled CYP2D6 NM | *10 still at activity 0.5 | Update activity table to Caudle 2020 (*10 = 0.25) |
| African patient suffers warfarin bleeding despite "wildtype" CYP2C9 | Panel omits *5/*6/*8/*11 (AFR-common) | Use ancestry-aware panel; supplement with INR-guided dosing |
| Severe thiopurine toxicity in TPMT-wildtype EAS patient | NUDT15 not tested | Always pair TPMT + NUDT15 |
| Patient with CYP2C19 *2/*2 and clopidogrel failure | Expected; no genotype-guided alternative chosen | Switch to prasugrel/ticagrelor per CPIC |
| DPYD AS = 0 but no dose adjustment | Single-variant rule used instead of activity score | Update to the CPIC activity-score framework |
| HLA-B*57:01 false positive | 2-field B*57 result misinterpreted | Re-type at 4-field |
Anticipated Reviewer Pushback
| Pushback | Standard response |
|---|
| "TAILOR-PCI missed primary endpoint; why genotype clopidogrel?" | Sensitivity analyses positive; Pereira 2021 meta-analysis (7 RCTs) +30% MACE reduction; ESC 2023 endorses; ACC 2022 weaker. |
| "DPYD universal screening is expensive" | Henricks 2018 per-variant toxicity reduction + Knikman 2021 cost-effective; EU standard since 2020; US ASCO/NCCN updated 2022-2024. |
| "CYP2D6 SV calling is unreliable" | Cyrius 99.3% on GeT-RM (Chen 2021); not unreliable; the prior tools were. |
| "*10 = 0.25 disagrees with old paper" | Caudle 2020 Clin Transl Sci consensus reset based on substrate-metabolic-ratio evidence. |
| "GeneSight is approved by my hospital" | GUIDED trial (Greden 2019) missed primary endpoint; physician-unblinded; literature shows modest effects inseparable from expectancy bias. |
| "Why pair TPMT + NUDT15?" | NUDT15 *3 is the dominant thiopurine determinant in East Asians (9.8% vs TPMT *3C ~2%); compound IM (TPMT + NUDT15) requires more aggressive dose reduction per Maillard 2026. |
| "HLA imputation from SNP array reliable?" | EUR-trained panel on EUR samples ~95%; cross-ancestry drops to 70-80%; for HSCT use sequencing-based typing. |
References
- Sangkuhl K et al. 2020. Pharmacogenomics Clinical Annotation Tool (PharmCAT). Clin Pharmacol Ther 107:203.
- Chen X et al. 2021. Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. Pharmacogenomics J 21:251.
- Numanagic I et al. 2018. Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun 9:828. (Aldy)
- Lee SB et al. 2019. Stargazer: a tool for calling star alleles. Genet Med 21:361.
- Twesigomwe D et al. 2020. A systematic comparison of pharmacogene star allele calling bioinformatics algorithms. npj Genom Med 5:30.
- Caudle KE et al. 2020. Standardizing CYP2D6 genotype to phenotype translation. Clin Transl Sci 13:116. (Activity-score reset for *10)
- Bank PCD et al. 2018. Comparison of the guidelines of the CPIC and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther 103:599.
- Amstutz U et al. 2018. CPIC guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210. (DPYD activity score)
- Swen JJ et al. 2023. PREPARE: A pre-emptive pharmacogenetic testing strategy. Lancet 401:347.
- Henricks LM et al. 2018. DPYD-guided dose individualization to fluoropyrimidines. Lancet Oncol 19:1459.
- Pereira NL et al. 2020. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after PCI. JAMA 324:761. (TAILOR-PCI)
- Pereira NL et al. 2021. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv 14:739.
- Mallal S et al. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. NEJM 358:568. (PREDICT-1)
- Chung WH et al. 2004. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486.
- McCormack M et al. 2011. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. NEJM 364:1134.
- Hung SI et al. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. PNAS 102:4134.
- Yang JJ et al. 2015. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance. J Clin Oncol 33:1235.
- Relling MV et al. 2019. CPIC guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 105:1095.
- PharmCAT documentation:
https://pharmcat.org
- PharmVar:
https://www.pharmvar.org
- CPIC:
https://cpicpgx.org
- DPWG:
https://www.knmp.nl/dpwg
Related Skills
- clinical-databases/hla-typing - HLA-B57:01, B15:02, B58:01, A31:01 typing
- clinical-databases/clinvar-lookup - Variant pathogenicity for non-PGx context
- clinical-databases/variant-prioritization - Rare-disease pipeline
- clinical-databases/myvariant-queries - Aggregated PGx variant annotation
- chemoinformatics/admet-prediction - Drug metabolism prediction
